Akebia Therapeutics Profit Margin

The latest profit margin for AKBA is -13.54% as of June 2026. That compares with -18.07% in the prior-year period — up 25.1% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Akebia Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AKBA's profit margin moved from -18.07% to -13.54% — a 25.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Akebia Therapeutics's valuation or profitability profile.

Against Healthcare companies, AKBA currently prints -13.54% for profit margin, while the sector average sits near 21.34%. That is roughly 163.5% below the sector mean. Large gaps often invite a closer look at Akebia Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Akebia Therapeutics converts resources into returns. At -13.54%, AKBA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -18.07% in the prior-year period — up 25.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AKBA's profit margin (-13.54%), review year-over-year change from -18.07%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.